Core Viewpoint - Inspira Technologies Oxy B.H.N. Ltd. has announced a private placement offering to raise capital for working capital and general corporate purposes, with the closing expected around December 30, 2024 [1][4]. Company Overview - Inspira Technologies is a pioneering company in respiratory support technology, focusing on life-support innovations [4]. - The company has developed the Augmented Respiration Technology (INSPIRA™ ART), which aims to transform the $19 billion mechanical ventilation market by providing an alternative for patients with acute respiratory failure [8]. - The INSPIRA ART can stabilize decreasing oxygen saturation levels within minutes without the use of traditional ventilators, allowing patients to remain awake during treatment [8]. Product Development - The INSPIRA™ ART100 system has received FDA 510(k) clearance for use in Cardiopulmonary Bypass procedures and has also obtained Israeli AMAR certification for Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures [9]. - Other products in development include the INSPIRA™ ART500, the INSPIRA™ Cardi-ART portable device, the VORTX orbiting Oxygen Delivery System, and the HYLA™ blood sensor, which are not yet tested or approved for human use [10]. Financial Details - The private placement consists of 4,608,715 ordinary shares and warrants at a combined purchase price of $0.70, with warrants having an exercise price of $1.10 per share and a term of eighteen months [4].

RA'ANANA, Israel, Dec. 16, 2024 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN, IINNW), ("Inspira Technologies," "Inspira" or the "Company"), a groundbreaking respiratory support technology company, announced the delivery of INSPIRA™ ART100 systems to its U.S. distributor, Glo-Med Networks Inc ("Glo-Med"). The systems were shipped in fulfilment of a purchase order issued by Glo-Med to Inspira.The delivered INSPIRA™ ART100 systems will be distributed to sales targets across hospitals on t ...

RA'ANANA, Israel, Dec. 4, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN), (Nasdaq: IINNW) ("Inspira Technologies", "Inspira" or the "Company"), a groundbreaking life support technology company, entered into a strategic collaboration with Westchester Medical Center in Valhalla, New York. Westchester Medical Center, the flagship hospital in the Westchester Medical Center Health Network, will evaluate the performance and effectiveness of the new U.S. Food and Drug Administration (FDA) ...

Core Insights - Inspira Technologies is hosting a webinar on November 11, 2024, to discuss its innovative life support technology [1][2] - The company has developed the INSPIRA™ ART, a device aimed at disrupting the $19 billion mechanical ventilation market by stabilizing blood oxygen levels without mechanical ventilation [2][4] - The INSPIRA™ ART is designed for patients with acute respiratory failure, allowing them to remain awake during treatment [4] Company Developments - The INSPIRA™ ART technology can elevate declining blood oxygen saturation levels in minutes, providing a potential alternative to traditional mechanical ventilators [2][4] - The device will be equipped with the HYLA™ blood sensor for real-time continuous blood monitoring, which alerts physicians to changes in a patient's condition [4] Market Potential - There are approximately 20 million intensive care unit patients with acute respiratory failure annually, many of whom currently rely on mechanical ventilators [4] - The innovative technology has the potential to significantly impact the mechanical ventilation market, which is valued at $19 billion [2][4]

Core Viewpoint - Inspira Technologies has signed a distribution agreement with Glo-Med Networks Inc, designating Glo-Med as the primary distributor and customer support center for Inspira's INSPIRA ART100 in the U.S. market, aiming to enhance operational efficiency and customer service capabilities [2][4]. Group 1: Distribution Agreement and Facility - The distribution facility located in Florida will support the deployment and maintenance of the INSPIRA ART100 system and may facilitate the commercialization of additional products in the U.S. market in the future [3]. - Glo-Med will fully operate the medical distribution and service facility, which will serve as a central hub for Inspira's logistics operations, ensuring timely and efficient distribution of the Company's medical devices [3]. - The facility will include a dedicated customer support team and provide certified after-market services through a partnership with Med-Stat Consulting Services [3]. Group 2: Product Overview and Market Potential - The INSPIRA ART100 has received FDA 510(k) clearance for Cardiopulmonary Bypass procedures and aims to revolutionize life support for millions of acute respiratory failure patients each year [2][6]. - The INSPIRA ART device targets 20 million patients annually and has an estimated market opportunity of $19 billion, offering an alternative to mechanical ventilators by stabilizing oxygen saturation levels without sedation [2][5]. - The INSPIRA ART is equipped with the HYLA blood sensor for real-time continuous blood monitoring, which aims to assist physicians in making informed decisions without the need for intermittent blood samples [5]. Group 3: Leadership Statements - Joe Hayon, co-founder and President of Inspira Technologies, emphasized that the distribution agreement is a crucial milestone for introducing Inspira's technologies to the market [4]. - Matus Knoblich, CEO of Glo-Med, expressed confidence that the collaboration will create a vertically integrated business model, enhancing service and support for customers [4].

RA'ANANA, Israel, Oct. 9, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira Technologies", "Inspira" or the "Company"), a groundbreaking respiratory support technology company, is pleased to announce the development of a new disposable kit for the perfusion market. This strategic move is central to Inspira's business strategy of generating recurring revenues for products to be deployed in conjunction with the INSPIRA ART100 and that are also intended to be co ...

Inspira Technologies OXY B.H.N. Ltd. (IINN) recently announced its significant appearance at the 34th Annual Extracorporeal Life Support Organization ("ELSO") conference in Detroit, MI. The ELSO conference will take place from Sept. 29 to Sept.30, 2024. At the conference, IINN will present its latest and future technologies, highlighting the company's commitment to innovation in extracorporeal blood circulation technologies. Impact of the News on IINN Stock Following the news, shares of IINN rose 0.8% to $1 ...

RA'ANANA, Israel, Sept. 24, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW), ("Inspira Technologies", "Inspira", or the "Company") a breakthrough medical technology company, is poised to make a significant impact at the 34th Annual Extracorporeal Life Support Organization (ELSO) Conference in Detroit, Michigan, on the 29th to the 30th of September 2024. The Company will be presenting its latest and future technologies, underscoring its commitment to innovation and excellence ...

To date, a combined total of 32 claims have been deemed novel for the core technology of the INSPIRA™ ART device Targeting treatment for 20 million ICU patients with respiratory failure annually, with many relying on mechanical ventilators, in a $19 billion industry RA'ANANA, Israel, Sept. 13, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company targeting to supersede mechanical ventilat ...

Inspira Technologies OXY B.H.N. Ltd. (IINN) recently announced plans to report clinical results for its new HYLA blood sensor in open-heart surgery patients. Since the medical industry is highly interested in the HYLA blood sensor, these clinical results should be on par with Inspira's long-term growth plans. About Inspira's HYLA Blood Sensor HYLA blood sensor is an advanced tubing clip-on sensor designed to monitor a patient's state in real-time by continuously measuring vital blood parameters. The clip-on ...